Evidence map›Paper›PMID 40993715›Full record

ArticleTropical medicine and health2025

Screening for Leishmania spp. infection in patients treated with biologic agents for immune-mediated inflammatory diseases: results of an Italian multicentric prospective study.

Emma Balducelli, Ana Torres, Sara Morselli, Andrea Angheben, Chiara Piubelli, Francesca Perandin, Salvatore Scarso, Cinzia Scambi, Alessandro Bartoloni, Lorenzo Zammarchi and 10 more

Abstract read
In one paragraph

Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Emma BalducelliDepartment of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.
Ana TorresWHO Collaborating Centre for Leishmaniasis, Spanish National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.
Sara MorselliDepartment of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.
Andrea AnghebenDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy.
Chiara PiubelliDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy.
Francesca PerandinDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy.
Salvatore ScarsoDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy.
Cinzia ScambiRheumatology Unit, Section of Rheumatology Department of Internal Medicine, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy.
Alessandro BartoloniDepartment of Clinical and Experimental Medicine, Università degli Studi di Firenze, 50134, Florence, Italy.
Lorenzo ZammarchiDepartment of Clinical and Experimental Medicine, Università degli Studi di Firenze, 50134, Florence, Italy.
Anna BarbieroDepartment of Clinical and Experimental Medicine, Università degli Studi di Firenze, 50134, Florence, Italy.
Filippo LagiInfectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Careggi, 50134, Florence, Italy.
Michele SpinicciDepartment of Clinical and Experimental Medicine, Università degli Studi di Firenze, 50134, Florence, Italy.
Francesca NacciSection of Rheumatology, Department of Clinical and Experimental Medicine, Università degli Studi di Firenze, 50125, Florence, Italy.
Margherita OrtalliDepartment of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.
Simone BaiocchiUnit of Microbiology, IRCSS Azienda Ospedaliero-Universitaria di Bologna, 40138, Bologna, Italy.
Lorena BernardoWHO Collaborating Centre for Leishmaniasis, Spanish National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.
Javier MorenoWHO Collaborating Centre for Leishmaniasis, Spanish National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.
Eugenia CarrilloWHO Collaborating Centre for Leishmaniasis, Spanish National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain. ecarrillo@isciii.es.
Stefania VaraniDepartment of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.

Funding

Instituto de Salud Carlos III PI22/00009Italian Ministry of Health RF-2016-02361931
6 · The paper itself

Abstract

backgroundEscalation in the use of biologic agents including tumor necrosis factor (TNF)-α inhibitors to treat immune-mediated inflammatory diseases (IMID) is linked to higher susceptibility of severe infections caused by intracellular pathogens, including Leishmania.

methodsThis multicentric prospective study assessed the presence of Leishmania spp. infection among patients with IMID under treatment with biologic agents in two Italian clinical centers. We utilized a combination of diagnostic tests: real-time PCR for the detection of parasitic kinetoplast DNA in peripheral blood, Western blot for the identification of serum IgG antibodies, and a Whole blood assay to assess cytokine and chemokine responses following stimulation with parasitic antigen.

resultsA total of 126 patients residing in Italy were enrolled. Patients testing positive in at least one assay were classified as Leishmania-positive. Of the 125 asymptomatic individuals, 25 (20%) tested positive for Leishmania infection, revealing a significant rate of subclinical infection. The most frequent marker of infection was positive serology (15/126, 12%) followed by a detectable cell-mediated immune response (9/125, 7%). Parasitic DNA was detected in 3 patients (2%).

conclusionsThis study showed a high prevalence of asymptomatic Leishmania infection in Italian patients with IMID under treatment with biologic agents, with a north-to-south gradient. Given the risk of disease reactivation, these patients may benefit from close monitoring. Further research is warranted to clarify the clinical implications of these findings.

Indexed as

Asymptomatic Leishmania infectionBiologic agentsImmune-mediated inflammatory diseasesLeishmania infantum

Identifiers

PMID40993715
PMCPMC12461971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.